Report: Radical New IVD Test Approaches Key To Growth
NEW YORK, Oct. 22, 2014 /PRNewswire/ -- New test innovations will be the source of revenue growth in the in vitro diagnostic (IVD) test industry, especially as companies struggle with reimbursement challenges, according to Kalorama Information. The healthcare market researcher listed more than 25 testing innovations in important disease areas in academic settings that could be the future of IVD products. Kalorama details the new approaches its biennial survey of the IVD industry, The Worldwide Market for In Vitro Diagnostic Tests, 9th Edition.
The report can be found at:
http://www.kaloramainformation.com/redirect.asp?progid=86567&productid=8326563.
"These innovations are really but the tip of the iceberg; this is a very exciting time for clinical diagnostics and these select innovations demonstrate the breadth of research and development underway," the report's author, Shara Rosen, said in the report.
There is a wealth of innovation underway in university and research laboratories, worldwide. Below a few of these tests in development are listed.
- miRNA Test for colorectal cancer - Scientists at the Baylor Research Institute analyzed 568 serum and tissue specimens that were obtained from healthy volunteers and consecutively enrolled patients with colorectal adenomas and cancers at the Mie University Medical Hospital (Tsu, Japan), between January 1, 2005 and December 31, 2010. A highly sensitive blood test can detect cancer related micro-ribonucleic acid (miRNA) before any signs of the disease manifests. By measuring levels of miR-21 in the blood, the scientists could accurately identify up to 92% of patients with colorectal cancer.
- Single-breath test for heart failure. The Respiratory Institute at Cleveland Clinic is developing a breath test, designed to identify patients suffering from heart failure by analyzing the contents of a single exhaled breath. They reported that the breath test correctly identified all the patients with heart failure, clearly distinguishing them from those cardiac cases where heart failure was not an issue. The findings were published March 25, 2013 in the Journal of the American College of Cardiology.
- SNP testing for childhood asthma risk - Researchers at the Duke University Center for the Study of Aging and Human Development are investigating a gene panel of 17 single nucleotide polymorphisms, linked to asthma. The goal is a genetic risk assessment that can provide information about whether childhood asthma will remit or persist. The study was published online in the journal Lancet Respiratory Medicine, June 2013.
- Urine PSA test. Researchers at UC Irvine have developed a new diagnostic that uses urine for prostate cancer screening with the Prostate-Specific Membrane Antigen. This would create a test that's easier to administer, as most traditional prostate cancer screening techniques use a patient's blood.
These are just a selection of the many diagnostic innovations from academic institutions that Kalorama believes will be implemented in commercial products.
The Worldwide Market for In Vitro Diagnostics, 9th Edition presents these innovative tests as well as other detailed market information. The report's coverage includes market sizing and forecasts for various IVD markets, a description of new technologies, customer needs and major suppliers with an eye on how they are shaping the IVD industry. Find the report along with other industry leading research from Kalorama Information at: http://www.kaloramainformation.com/Worldwide-Vitro-Diagnostic-8326563/.
About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Logo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Share this article